#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14760	16S	1529	1529	99.8	16S.l15.c4.ctg.1	2034	718.0	0	.	n	.	0	T536C	SNP	536	536	T	737	737	C	868	C,T	624,204	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14760	16S	1529	1529	99.8	16S.l15.c4.ctg.1	2034	718.0	0	.	n	.	0	T1157C	SNP	1157	1157	T	1358	1358	C	844	C,T,A,G	700,2,1,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14760	16S	1529	1529	99.8	16S.l15.c4.ctg.1	2034	718.0	0	.	n	.	0	C1450T	SNP	1450	1450	C	1651	1651	T	796	T,C	745,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	14760	16S	1529	1529	99.8	16S.l15.c4.ctg.1	2034	718.0	1	SNP	n	C1184T	0	.	.	1184	1184	C	1385	1385	C	865	C,A	804,1	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27190	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3588	755.8	0	.	n	.	0	C1623T	SNP	1623	1623	C	1958	1958	T	933	T,C	826,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27190	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3588	755.8	0	.	n	.	0	T1971C	SNP	1971	1971	T	2306	2306	C	859	C,A	800,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27190	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3588	755.8	1	SNP	n	A2045G	0	.	.	2045	2045	A	2380	2380	A	865	A	822	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	27190	23S	2890	2890	99.93	23S.l6.c30.ctg.1	3588	755.8	1	SNP	n	C2597T	0	.	.	2597	2597	C	2932	2932	C	840	C	792	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	2122	folP	855	855	100.0	folP.l15.c4.ctg.1	1475	143.1	1	SNP	p	R229S	1	.	.	685	687	AGC	1012	1014	AGC	198;201;200	A;G;C	184;187;184	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5368	gyrA	2751	2751	99.82	gyrA.l6.c4.ctg.1	3318	161.1	0	.	p	.	0	M250I	NONSYN	748	750	ATG	1041	1043	ATA	166;167;166	A;T;A	152;155;151	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5368	gyrA	2751	2751	99.82	gyrA.l6.c4.ctg.1	3318	161.1	1	SNP	p	S91F	0	.	.	271	273	TCC	564	566	TCC	193;191;187	T;C;C	186;183;179	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5368	gyrA	2751	2751	99.82	gyrA.l6.c4.ctg.1	3318	161.1	1	SNP	p	D95G	0	.	.	283	285	GAC	576	578	GAC	193;195;191	G;A;C	181;183;180	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	5368	gyrA	2751	2751	99.82	gyrA.l6.c4.ctg.1	3318	161.1	1	SNP	p	D95N	0	.	.	283	285	GAC	576	578	GAC	193;195;191	G;A;C	181;183;180	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_L_00489c	mtrR.WHO_L_00489c	1	1	27	1680	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1267	131.9	1	SNP	p	G45D	1	.	.	133	135	GAC	413	415	GAC	205;206;208	G;A;C	195;196;196	mtrR.WHO_L_00489c:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	928	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	984	93.9	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5336	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3031	175.5	1	SNP	p	D86N	0	.	.	256	258	GAC	666	668	GAC	213;214;212	G;A;C	198;196;196	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5336	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3031	175.5	1	SNP	p	S87W	0	.	.	259	261	AGT	669	671	AGT	209;208;208	A;G,A;T	194;192,1;191	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5336	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3031	175.5	1	SNP	p	S87I	0	.	.	259	261	AGT	669	671	AGT	209;208;208	A;G,A;T	194;192,1;191	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5336	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3031	175.5	1	SNP	p	S87R	0	.	.	259	261	AGT	669	671	AGT	209;208;208	A;G,A;T	194;192,1;191	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5336	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3031	175.5	1	SNP	p	S88P	0	.	.	262	264	TCC	672	674	TCC	208;210;209	T;C;C	193;195;195	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4448	parE	1986	1986	100.0	parE.l15.c4.ctg.1	2630	168.7	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1580	1582	GGC	215;212;207	G;G;C	201;198;193	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	4002	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2291	173.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1186	1188	GCA	211;211;211	G;C,G;A	203;203,1;206	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4002	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2291	173.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1189	1191	ATC	211;215;219	A,G;T;C,T	205,1;208;210,1	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4002	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2291	173.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1201	1203	GTG	215;214;215	G;T;G,T	202;201;203,1	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4002	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2291	173.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1201	1203	GTG	215;214;215	G;T;G,T	202;201;203,1	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4002	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2291	173.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1705	1707	ACC	207;206;206	A;C;C,A	184;189;187,1	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4002	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2291	173.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1759	1761	GCG	206;204;209	G;C;G	185;173;180	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4002	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2291	173.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1759	1761	GCG	206;204;209	G;C;G	185;173;180	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4002	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2291	173.8	1	SNP	p	G543S	0	.	.	1627	1629	GGT	1882	1884	GGT	173;175;177	G,A;G;T	162,1;166;163	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4002	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2291	173.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1891	1893	GGC	175;171;168	G;G;C,G	163;158;156,1	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	4002	penA	1752	1752	100.0	penA.l6.c4.ctg.1	2291	173.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1909	1911	CCG	162;166;163	C,G;C;G	115,1;138;126	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	539	5930	ponA	2397	2397	99.92	ponA.l6.c30.ctg.1	3054	193.5	0	.	p	.	0	T692M	NONSYN	2074	2076	ACG	2385	2387	ATG	244;245;244	A;T;G	195;211;211	.	.
ponA.WHO_F_00106	ponA.WHO_F_00106	1	1	539	5930	ponA	2397	2397	99.92	ponA.l6.c30.ctg.1	3054	193.5	1	SNP	p	L421P	0	.	.	1261	1263	CTG	1572	1574	CTG	224;226;222	C;T;G	195;199;195	ponA.WHO_F_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2324	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1746	132.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	502	502	C	161	C	146	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2928	porB1b	1035	1035	98.85	porB1b.l6.c17.ctg.1	1733	168.1	0	.	p	.	0	R143G	NONSYN	427	429	AGA	728	730	GGA	215;218;221	G;G;A	206;208;208	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2928	porB1b	1035	1035	98.85	porB1b.l6.c17.ctg.1	1733	168.1	0	.	p	.	0	.	INDELS	629	630	AA	931	933	TAG	258;263;261	T;A;G	239;243;243	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2928	porB1b	1035	1035	98.85	porB1b.l6.c17.ctg.1	1733	168.1	0	.	p	.	0	.	INDELS	631	633	TAC	935	940	CAATCT	255;259;258;255;259;262	C;A;A,T;T;C;T	237;241;237,1;236;240;245	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2928	porB1b	1035	1035	98.85	porB1b.l6.c17.ctg.1	1733	168.1	0	.	p	.	0	N212Y	NONSYN	634	636	AAT	941	943	TAT	260;262;267	T;A;T	244;244;246	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2928	porB1b	1035	1035	98.85	porB1b.l6.c17.ctg.1	1733	168.1	0	.	p	.	0	L218F	NONSYN	652	654	CTT	959	961	TTT	263;263;263	T;T;T	242;244;246	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2928	porB1b	1035	1035	98.85	porB1b.l6.c17.ctg.1	1733	168.1	0	.	p	.	0	S254R	NONSYN	760	762	AGT	1067	1069	CGT	255;257;253	C;G;T	236;241;237	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2928	porB1b	1035	1035	98.85	porB1b.l6.c17.ctg.1	1733	168.1	0	.	p	.	0	A268V	NONSYN	802	804	GCG	1109	1111	GTG	248;248;248	G;T;G	229;229;228	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2928	porB1b	1035	1035	98.85	porB1b.l6.c17.ctg.1	1733	168.1	1	SNP	p	G120K	0	.	.	358	360	GGT	659	661	GGT	218;218;216	G;G;T	209;207;200	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2928	porB1b	1035	1035	98.85	porB1b.l6.c17.ctg.1	1733	168.1	1	SNP	p	A121N	0	.	.	361	363	GCC	662	664	GCC	216;212;217	G;C;C	203;204;210	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	2928	porB1b	1035	1035	98.85	porB1b.l6.c17.ctg.1	1733	168.1	1	SNP	p	A121D	0	.	.	361	363	GCC	662	664	GCC	216;212;217	G;C;C	203;204;210	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	27	10892	rpoB	4179	4179	100.0	rpoB.l6.c30.ctg.1	4817	225.4	1	SNP	p	H553N	0	.	.	1657	1659	CAT	1984	1986	CAT	225;233;232	C,A;A;T	214,1;224;223	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1148	rpsJ	312	312	100.0	rpsJ.l15.c30.ctg.1	1244	92.2	1	SNP	p	V57M	1	.	.	169	171	ATG	647	649	ATG	252;253;251	A;T;G	236;236;233	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
tetM.WHO_G_pTetM_00047	tetM.WHO_G_pTetM_00047	1	0	27	13076	tetM	1920	1920	100.0	tetM.l6.c30.ctg.1	2697	483.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Tetracycline resistance
